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P3 is a murine IgM mAb that recognize N -glycosylated gangliosides, sulfatides, and anti-
gens expressed in melanoma, breast, and lung human tumors.This antibody has the ability
to trigger an IgG antibody response in the syngeneic BALB/c model, even when it is admin-
istered in the absence of adjuvant or carrier protein.The mechanism by which the P3 mAb,
a self-immunoglobulin, induce this immune response in the absence of co-stimulatory
or classical danger signals is still unknown. In the present paper we show that the high
immunogenicity of P3 mAb depends not only on CD4 but also on CD8+ T cells, since
the depletion of CD8+ or CD4+ T cells led to the loss of P3 mAb immunogenicity in the
syngeneic model. Furthermore, the immunization with P3 mAb enhanced the recovery of
the CD8+ T cell population in mice treated with an anti-CD8a antibody. Additionally, the
immunization with P3 mAb restored the capacity of immunosuppressed mice to reject
allogeneic tumors, a mechanism mediated by the action of CD8+ T cells. Finally, in mice
with cyclophosphamide induced lymphopenia, the administration of P3 mAb accelerated
the recovery of both CD4+ and CD8+ T cells. These results show new possibilities for B
and CD8+ T cells interactions during the immune response elicited by a self-protein. Fur-
thermore they point to P3 mAb as a potential interesting candidate for the treatment of
immunosuppressed patients.
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INTRODUCTION
P3 mAb is an Ab1 antibody that recognizes NeuGc-containing
gangliosides, sulfated glycolipids, and antigens present in differ-
ent human tumors including those from the lung, breast, and
melanoma (Vazquez et al., 1995). VH P3 is of germ line origin and
belongs to the Q52 (VH II) gene family, previously observed in
autoantibodies against gangliosides and frequently used by CD5+
B lymphocytes (Perez et al., 2001). This antibody is capable of
triggering a strong anti-idiotypic (Ab2) response in the syngeneic
model, even in the absence of adjuvant or carrier protein (Vazquez
et al., 1998), which is a phenomenon rarely observed (Baskin et al.,
1990; Maruyama et al., 2002).
Some authors have suggested that the IgM isotype confers cer-
tain advantages for the development of anti-idiotypic responses
(Baskin et al., 1990; Reitan and Hannestad, 1995, 2002), but
it has been shown that this is not a general property of the
IgM anti-ganglioside antibodies (Vazquez et al., 1998; Reitan and
Hannestad, 2001), which suggest that the variables regions of
the immunogenic antibodies could contain antigenic determi-
nants that could be responsible for their unusual immunogenicity.
In fact, the immunogenicity of P3 mAb idiotype has also been
demonstrated in the absence of any constant domain (Rodriguez
et al., 2007). Some authors have shown that the presence of somatic
hypermutations is an important factor in the immunogenicity of
autologous immunoglobulins (Zaghouani et al., 1992; Eyerman
and Wysocki, 1994; Cao et al., 1995; Eyerman et al., 1996; Wysocki
et al., 1998; Zhang et al., 2001). However, P3 mAb variable region
is coded by germ line genes (Perez et al., 2001), so the presence
of somatic hypermutations is not the cause of its high immuno-
genicity (Rodriguez et al., 2007). In fact, Reitan and Hannestad
(2001) analyzed the syngeneic immunogenicity, in the absence
of adjuvant, of the idiotypes of 73 mAb of IgM isotype. These
researchers reported that the four antibodies that generated high
levels of anti-idiotypic IgG antibodies, were coded by germ line
genes.
Based on structural modeling and immunogenetic analysis,
several P3 mAb mutants were obtained by substituting the basic
residues R31, R98, and R100a, of the H-CDRs of the variable
regions of P3. Immunization experiments with these mutants
proved that these basic residues play a critical role in both its bind-
ing speciﬁcity and high immunogenicity (Lopez-Requena et al.,
2007a,b).
The fact that P3 mAb induces anti-idiotypic antibodies of
IgG isotype suggests the participation of T cells in the genera-
tion of this response. This is very interesting since P3 is a self-
immunoglobulin, presented to the immune system in the absence
of the classical co-stimulatory signals (Caux et al., 1994; Tseng
et al., 2001). Previous data already published by our group showed
that lymph node cells from BALB/c mice immunized with P3 mAb
proliferated in vitro, in a dose-dependent manner, not only in the
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presence of P3 mAb but also in the presence of 1E10, one of its
anti-idiotypic Ab2 mAb. This result suggests that P3 mAb is able
to activate B–T cell idiotypic networks (Perez et al., 2002).
All these results prompted us to evaluate the immunogenicity
of P3 mAb in different mouse strains, and to study the impor-
tance of different T cell populations in the induction of this
unusual anti-idiotypic response,which could contribute to under-
stand the mechanism underlying this unusual immunogenicity.
Although for many years it was believed that the Th1/Th2 par-
adigm only applied to CD4+ T cells, several studies have shown
that CD8+ T cells can also provide B cell help (Jacobsen et al.,
1993; Cronin et al., 1995; Hermann et al., 1995). Thus in the
present work we wanted to study the contribution of both CD4+
and also CD8+ T cells in the induction of an anti-idiotypic
response.
RESULTS
HUMORAL RESPONSE TO P3 mAb
Three important factors to characterize the immune response
against a given antigen are the kinetic of the response, the inﬂu-
ence of the immunization route, and the importance of the use
of an adjuvant to achieve the response. To assess the signiﬁcance
of these factors for P3 mAb immunogenicity, ﬁrst, BALB/c mice
were immunized intraperitoneally, intramuscularly, or subcuta-
neously with four doses of this antibody in phosphate buffered
saline (PBS). We detected an antibody response against P3 mAb
in most immunized animals regardless the route of immunization
used. However the level of the antibody response was signiﬁcantly
higher in animals immunized subcutaneously (Figure 1).
Next we studied if the presence of an adjuvant changes P3
immunogenicity. For this purpose we evaluated the IgG antibody
FIGURE 1 | IgG antibodies response in BALB/c mice immunized with
P3 mAb using different routes of immunization. BALB/c mice were
immunized with four doses of P3 mAb in PBS using different routes of
immunization: subcutaneously (s.c.), intraperitoneally (i.p.), or intramuscular
(i.m.). The blood samples were obtained before the immunization and
7 days after the second, third, and fourth doses (days 21, 35, and 49 of the
immunization protocol). Sera were diluted 1:100 and the response against
puriﬁed P3 mAb was assessed by ELISA, reactivity was determined using
alkaline phosphatase-conjugated goat anti-mouse IgG (Fcγ-speciﬁc). Values
are expressed as means±SD (n = 5). *p< 0.05, Mann–Whitney U test,
one-tailed.
response induced in BALB/c mice immunized subcutaneously
with P3 only in PBS or emulsiﬁed in Freund’s adjuvant. Fur-
thermore we compare the response induced in mice that received
four doses of P3 mAb at 2weeks intervals or a single dose of
the antibody. As is shown in Figure 2, the mice immunized
with four doses of P3 mAb generated an antibody response
of the IgG isotype independently on the use of Freund’s adju-
vant. This response was speciﬁc for P3 mAb idiotype since did
not cross react with an irrelevant IgM used as isotype control
(Figure A1 in Appendix). The response was detected from the
second dose for the animals immunized with adjuvant and from
the third for those immunized only with P3/PBS. Furthermore,
mice immunized with a single dose of P3 mAb in the presence of
Freund’s adjuvant, elicited an IgG antibody response detectable
at day 21 after immunization, moment equivalent to the sec-
ond dose of the mice that received four doses. Although these
mice received only one dose of P3 mAb, the anti-P3 antibody
response continued increasing in time and 49 days after immu-
nization reached levels that did not show signiﬁcant differences
with those obtained in the animals immunized with four doses.
We could not detect any antibody response of the IgG isotype
in the animals that received only one dose of P3 mAb in PBS
(Figure 2).
Since P3 mAb has the rare ability to generate humoral immune
response in the syngeneic BALB/c model, we wanted to estab-
lish whether it was equally immunogenic in a different mouse
strain, like C57BL/6. The Figure 3 showed that, in contrast with
the results obtained in syngeneic BALB/c mice (Figure 3A), in the
allogeneic inbred mice strain C57BL/6, after four doses of P3 mAb
immunization we could not detected any signiﬁcant IgG antibody
response at the dilution used (Figure 3B). However in the outbred
NMRI mice strain we could detect a signiﬁcant IgG response after
four doses in all the mice tested (Figure 3C).
FIGURE 2 | Kinetic of IgG antibodies response in BALB/c mice. Mice
were immunized with one (1d) or four (4d) doses of P3 mAb in PBS or
emulsiﬁed in Freund’s adjuvant (FA). The blood samples were obtained
before the immunization and on days 7, 21, 35, and 49 of the immunization
protocol. Sera were diluted 1:100 and the reactivity against puriﬁed P3 mAb
was assessed by ELISA. Binding was determined using alkaline
phosphatase-conjugated goat anti-mouse IgG (Fcγ-speciﬁc). Values are
expressed as means±SD (n = 5).
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FIGURE 3 | Immunogenicity of P3 mAb in different mice strains. BALB/c
(A), C57BL/6 (B), or NMRI (C) mice were immunized subcutaneously with
four doses of P3 mAb in PBS every 2weeks. The sera samples were taken
before the immunization period (day 0) and after the third (day 35) and fourth
(day 49) dose. The reactivity was determined by ELISA in P3 mAb coated
plates using alkaline phosphatase-conjugated goat anti-mouse IgG
(Fcγ-speciﬁc). For each mouse, is graphed the means±SD of each of the
values obtained in triplicate.
IMPORTANCE OF T CELLS IN THE ANTIBODY RESPONSE AGAINST
P3 mAb
Since the immunization with P3 mAb induce antibodies of IgG
isotype and depends on the mouse strain, next we evaluated the
participation of T cells in the induction of this antibody response.
For this purpose CD4+ or CD8+ T cells were depleted with anti-
CD4 or anti-CD8a antibodies at different moments during the
immunization protocol and the antibody response after the fourth
dose was tested by ELISA. As is shown in Figure 4, a signiﬁcant
decrease in the antibody response was detected in the sera of the
animals treated before the ﬁrst dose of P3 mAb (group 2), with the
anti-CD4 (Figure 4A) but also in those treated with the anti-CD8a
antibody (Figure 4B). There were not signiﬁcant differences in the
response of the groups treated before the second and the third dose
with any of the depleting antibodies (group 3 and 4; Figure 4C).
IN VIVO RESTORATION OF CD8+T LYMPHOCYTES BY P3 mAb
Due to the involvement of CD8+ T cells in the induction of the
antibody response against P3 mAb, we studied if the immuniza-
tion with this antibody increase the percentage of CD8+ T cells
in the inguinal lymph node of BALB/c mice treated with the
anti-CD8a antibody. The results showed that the percentage of
CD8+ T cells in mice immunized with P3 mAb was signiﬁcantly
higher than the one detected in mice treated with the control anti-
body or PBS (Figure 5A). In the C57BL/6 strain, where P3 is not
immunogenic, we could not detect any difference in the CD8+ T
cells percentage between the mice immunize with P3 or with the
controls (Figure 5B).
EFFECT OF P3 mAb IN F3II MEDIATED ENGRAFTMENT OF ALLOGENEIC
B16-F10 TUMOR IN BALB/c MICE
Next we tested the ability of this antibody to stimulate an immune
system affected for the presence of a tumor. We used a model
of tumor induced immunosuppression where BALB/c mice were
inoculated with the syngeneic F3II tumor cells, which make them
susceptible to the engraftment of the allogeneic B16-F10 tumor
cells. One week before the syngeneic tumor inoculation the mice
received the ﬁrst of four, biweekly, doses of P3 mAb, and the allo-
geneic tumor development on immunized and not treated mice
was compared. As shown in Figure 6, the immunization with
P3 mAb increased the percentage of animals able to reject the
allogeneic tumor. Fifty percent of non-immunized mice devel-
oped allogeneic B16-F10 in comparison with only 19% of P3 mAb
immunized mice. P3 mAb did not have any effect on the kinetics
of engraftment or the tumor size in the mice that did not reject
the allogeneic tumor (data not shown).
CAPACITY OF P3 mAb TO RECOVERY T CELL POPULATIONS IN
LYMPHOPENIC MICE
To further evaluate the therapeutic potential of this antibody, we
tested the ability of P3 mAb to stimulate in vivo the recovery
of different lymphocyte populations in a model of induced lym-
phopenia (Zuluaga et al., 2006) that resemble the state of immune
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FIGURE 4 | Differences in the IgG antibodies response against P3 mAb in
BALB/c mice treated in different moments of the protocol with CD4a or
CD8a depleting antibodies. BALB/c mice were immunized with four doses
of P3 mAb in PBS and were treatment with an anti-CD4a (A) or anti-CD8a (B)
depleting antibody only once before one of the dose of P3 (except the fourth).
Sera were diluted 1:100 and the reactivity against puriﬁed P3 mAb was
assessed by ELISA. Binding was determined using alkaline
phosphatase-conjugated goat anti-mouse IgG (Fcγ-speciﬁc). (C) A
representative effect on CD8+ cell populations of the treatment with one
dose of anti-CD8a depleting antibody, upper ﬁgure showed control mouse
and lower ﬁgure showed treated mouse. Values are expressed as
means±SD (n = 5). *p< 0.05, Mann–Whitney U test, one-tailed.
suppressed patients. BALB/c mice treated with cyclophosphamide
were inoculated with P3 or an irrelevant mAb, and the recovery of
the lymphocyte populations was measured by ﬂow cytometry. As
is shown in Figure 7, mice that received P3 mAb and not the ones
treated with the control mAb, showed a signiﬁcant increase in the
percentage of CD4+ and CD8+ T populations after the cyclophos-
phamide treatment. Mice that received only cyclophosphamide or
cyclophosphamide plus control mAb showed 18–21% of CD4+ T
cells and 14–19% of CD8+ T cells regarding the normal cell num-
ber in not immune-compromised mice. However P3 treated mice
showed an increase up to 46% for CD4+ T and 50% for CD8+ T
cells. There were no signiﬁcant differences in the B cells percent-
ages between the different groups (Figure 7). This result is not
observed in C57BL/6 mice where we could not detect differences
between the controls and the mice treated with P3 mAb (data not
shown).
DISCUSSION
The high immunogenicity of autologous immunoglobulins is not
a phenomenon frequently observed (Ismaili et al., 1995), and in
particular the generation of a response against anti-ganglioside
mAb in the syngeneic model has been reported in very few studies,
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FIGURE 5 | Regeneration of the population of CD8+ T cells by the
action of the P3 mAb. BALB/c (A) or C57BL/6 (B) mice inoculated with
P3 mAb, control mAb (E1), or PBS were intraperitoneally treated with
anti-CD8a depleting antibody. The expression of the CD8a molecule in
lymph node cells was determined by ﬂow cytometry for which the cells
were incubated with a ﬂuorescein isothiocyanate-conjugated anti-mouse
CD8a. Values represent means±SD (n = 8). *p< 0.05, Dunnett t -test,
one-tailed.
FIGURE 6 | Immunization with P3 mAb retrieves the ability of
allogeneic MB16F10 tumor rejection in BALB/c mice
immunosuppressed by syngeneic F3II tumor. Mice inoculated with F3II
tumor and treated or not with P3 mAb were challenged with MB16F10
tumor. The bars indicate the percentage of mice developing tumors. The
values represent the mean of two different experiments. Ctrl-: BALB/c mice
that were not inoculated with F3II tumor, Ctrl+: C57BL/6 mice, in which the
tumor MB16F10 are syngeneic. *p< 0.05, Pearson’s chi-square (χ2) test,
one-tailed.
always using adjuvant or carrier protein (ChapmanandHoughton,
1991; Saleh et al., 1993). However, P3 mAb is a germline anti-
NeuGcGM3 IgM that is highly immunogenic, in the absence of
adjuvant or carrier protein, in the syngeneic model. Furthermore,
the immunization with this antibody induces not only B cell, but
also T cell idiotypic networks (Perez et al., 2002). The ﬁrst aim of
our work was to further study the high immunogenicity of this
antibody and to evaluate the role of T cells in this phenomenon.
There have been reports about variations in the induction of
humoral responses against a given antigen depending on the route
of inoculation used (Fynan et al., 1993; Raz et al., 1994). Although
we detected an antibody response against P3 mAb when it was
inoculated by subcutaneous, intramuscular, or intraperitoneal
route, this response was signiﬁcantly higher by the subcutaneous
immunization. This could be related with a slower speed of anti-
gen release or due to differences in the speciﬁc APC populations
in the site of immunization.
The generation of an antibody response against a proteic anti-
gen, such as antibodies, is generally favored by the number of doses
and by the presence of adjuvant (Cox and Coulter, 1997; Stills,
2005). When P3 mAb was inoculated only in PBS, at least three
doses were necessary to induce the immune response. However
when it was inoculated in the presence of Freund’s adjuvant, only
one dose was enough to induce an IgG response that had not sig-
niﬁcance differences, regarding the magnitude or the kinetic, with
the one achievedwith four doses. This result conﬁrms the ability of
this antibody to be autoimmunogenic in the syngeneic model and
suggest that the slow release of small amounts of the antibody to
the circulation, induced by the depot effect of the adjuvant, favor
the induction of a strong immune response. On the other hand
this could be a result of the capacity of this antibody to activate T
cell idiotypic networks (Perez et al., 2002; Rodriguez et al., 2007).
Evidence that suggest the participation of T cells in the anti-
P3 response is the fact that despite the high immunogenicity in
BALB/c mice, there was no antibody response against P3 mAb
after the immunization of C57BL/6 mice with four doses of the
mAb in PBS. These differences in the humoral response against
P3 mAb between in different mice strains could be because T
cells recognize P3 mAb epitopes presented by BALB/c strain spe-
ciﬁc MHC haplotypes, as has been described for other antigens
(Misharin et al., 2009). On the other hand, P3 mAb also induced
an anti-idiotypic response inNMRImice, an outbred strain, show-
ing that its immunogenic properties are not exclusive for BALB/c
mice haplotype.
An interesting result of our experiments was that not only the
depletion of CD4+ T cells, but also of CD8+ T cells, deeply affected
the induction of the anti-idiotypic response. The depletion of the
CD4+ or CD8+ T cells before the ﬁrst dose of P3 abrogated the
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FIGURE 7 | Recovery of the populations of CD4+ and CD8+ T cells by
immunization with P3 mAb in BALB/c mice treated with
cyclophosphamide. Mice were inoculated with two doses of
cyclophosphamide and then received an intravenous dose of the P3 mAb or
control mAb (E1). It was determined the amount of cells in inguinal lymph
nodes (A), and subpopulations of CD4+ T (B), CD8+ T (C), and B cells (D) by
ﬂow cytometry. It is considered as 100% the number of cells from animals
not treated with cyclophosphamide (PBS group). Values represent
means±SD (n = 5) in a representative experiment of three. *p< 0.05,
Dunnett t -test, one-tailed.
antibody response, suggesting an important role for these cells at
the ﬁrst stages of the anti-idiotypic response. Although historically
CD8+ T cells have been regarded as cytotoxic cells, several studies
have shown their capacity to activate the immune responses, pro-
viding help for DC (Nakamura et al., 2007), NK (Shanker et al.,
2007), and B cells (Cronin et al., 1995). It has become clear the
existence of CD8+ T cell subsets analogous to the Th1 and Th2
CD4 counterparts in mice (Croft et al., 1994; Cronin et al., 1995;
Sad et al., 1995) and humans (Salgame et al., 1991; Maggi et al.,
1994; Birkhofer et al., 1996).
On the other hand, the antibody response in BALB/c mice deﬁ-
cient of CD8+ T cells, immunized with P3 mAb emulsiﬁed in
Freund’s adjuvant, does not vary signiﬁcantly with respect to the
response in the mice with a normal CD8+ T cell population (data
not shown). The action of the adjuvant to enhance the immune
response, by activating dendritic cells (Salem et al., 2006; Agger
et al., 2008), might counteract the effect caused by the deﬁciency
of CD8+ T cells. These results suggest that in the induction of
an anti-P3 antibody response, CD8+ T cells could play a role
equivalent to that of an adjuvant, probably as activators of the
antigen presenting cells or directly activating the anti-idiotypic
antibody secreting B cell (Lu et al., 2002). Another possible role
of CD8+ T cells could be to eliminate or suppress some regula-
tory cell populations (Hahn et al., 2005), that could inhibit the
induction of the antibody response against P3 mAb. Although the
interaction between Id+ B cell and CD4+ T cells have been previ-
ously published (Weiss and Bogen, 1991; Bogen and Weiss, 1993;
Munthe et al., 1999; Jacobsen et al., 2010), to our knowledge, this
is the ﬁrst report that involves CD8+ T cells in the induction of an
anti-idiotypic response in vivo. This result opens new possibilities
for the understanding of the regulation and activation of B cell–T
cell idiotypic networks.
Due to the importance of CD8+ T cells for the humoral
response against P3, and knowing that P3 mAb is able to induce
T cells proliferation in vitro (Perez et al., 2002), we studied if this
antibody could have some impact on the CD8+ T cell population
in vivo. First we depleted the CD8+ populations in mice that were
treated with P3 mAb or an irrelevant control antibody. In fact,
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the percent of CD8+ T cell recovery in CD8+ cells depleted mice
previously immunized with P3 was signiﬁcantly higher than the
one detected in the animals treated with the control antibody. This
result demonstrated that P3 mAb has the ability to help the recov-
ery of the CD8+ T population in vivo. This could be a consequence
of a proliferative effect over the remnant or new emerging CD8+
T cells or due to the induction of a greater resistance to deple-
tion by the cytotoxic antibody. Since the anti-CD8a antibody used
cause complement dependent cell death (Cobbold et al., 1984),
the induction of CD8+ T cell proliferation due to immunization
would be the most suitable explanation.
In order to evaluate the functionality of the expanded T cells
and the capacity of P3 mAb to reactivate an immunosuppressed
immune system, we used an in vivo model. In this model BALB/c
mice become susceptible to an allogeneic tumor, which would be
rejected in immunocompetent mice, due to the immunosuppres-
sion inducedby the inoculationof a syngeneic tumor. In our exper-
iment, 50% of the BALB/c mice inoculated with the syngeneic
breast tumor F3II showed B16-F10 allogeneic tumor growth, in
contrast with only 19% on P3 treated mice. This result conﬁrms
that P3 mAb is able to recover functional T cells in situations of
immunosuppression (Sauer et al., 2008).
Next we evaluated the capacity of P3 mAb to induce the recov-
ery of T cell populations in a clinically relevant scenario, like the
immunosuppression induced by cytotoxic drugs during cancer
treatments. We could conﬁrm that in mice immunosuppressed
due to cyclophosphamide treatment, which affect both T and B
cell populations (Zuluaga et al., 2006), the treatment with a single
dose of P3 mAb also induced a signiﬁcant increase in the recov-
ery of CD4+ and CD8+ T. The same experiment performed in
C57BL/6 mice did not show signiﬁcant differences between the
P3 mAb immunized and non-immunized mice (data not shown).
This result conﬁrms the ability of P3mAb to induceT lymphocytes
proliferation in BALB/c mice.
The results in this work conﬁrm the high immunogenicity
of P3 mAb and proved the participation of CD8+ T cells dur-
ing the induction phase of the immune response. Moreover, we
showed that the immunization with P3 mAb reconstitutes in vivo
T cell populations and improve immunosuppressed states in lym-
phopenic BALB/c mice. A fast reconstitution of T cell dependent
immunity is a critical issue for patients treated with lymphode-
pleting regimens, which can produce higher susceptibility to
infections, reduced response to vaccines and easier tumor relapse
(Nordoy et al., 2001; Parkman et al., 2006; Aoki et al., 2012).
Some molecules with immunorestorative properties are being
evaluated, which include IL-7, IL-2, and IL-15. IL-7 has shown a
potent immunorestorative and vaccine adjuvant effects in preclin-
ical studies. Several clinical trials with IL-7 are ongoing in settings
of acquired immunodeﬁciency, chronic viral infection, and cancer,
showing so far to be well tolerated and to induce immunorestora-
tion, preferential of naïve T cells (Mackall et al., 2011). IL-2 has
beenused toboost effector immune responses inpatientswith can-
cers and infectious diseases and it is registered for the treatment
of renal-cell carcinoma. However, the response to the treatment
is achieved in less than 10% of the patients, probably because
this cytokine stimulates regulatory T cells, which could suppress
antitumor responses (Lemoine et al., 2009).
IL-15 is a potent proinﬂammatory cytokine, with antitumor
effects in several preclinical mouse tumor models. However,
administration of IL-15 alone was not optimal because it also acti-
vated immune system negative regulatory checkpoints that might
affect the immune response (Yu et al., 2010).
In this article we show the ﬁrst evidences that P3 mAb could
improve immune restoration, especially for T cells. To our knowl-
edge, this is the ﬁrst report of an immunogenic antibody with this
capacity. The negative impact of lymphopenia for cancer patients
and the fact that in this moment there is not a product that has
totally prove its effectiveness in the clinic;make it worthy to further
study this important property of P3 mAb. Furthermore, P3 has an
especial characteristic that differentiates it from the rest of the
molecules evaluated as immune-stimulators: P3 it is an antibody
and it would be possible the active induction of P3-like antibod-
ies sharing this property by anti-idiotypic immunization. In fact,
1E10 mAb, P3 mAb anti-idiotype has been used in several clini-
cal trials in lung, melanoma, and breast cancer patients, showing
that is able to induce a speciﬁc“P3-like”anti-NeuGcGm3 response
(Alfonso et al., 2002; Diaz et al., 2003; Hernandez et al., 2008).
Experiments to further study the phenotypes and functions
of the induced T cell populations in immune compromise mice
as well as to further understand the role of CD8+ T cells in the
activation of immune networks are ongoing.
MATERIALS AND METHODS
ANIMALS
Female BALB/c, C57BL/6, and NMRI mice, 6–8weeks old, were
purchased from the Center for Laboratory Animal Production
(CENPALAB, Havana, Cuba). Animals were housed and bred in
a barrier maintained room according to the guidelines stipulated
by the Animal Subject Committee Reviews Board at the Center of
Molecular Immunology (CIM). Animal studies were performed
with approval from CIM’s Institutional Animal Care and Use
Committee.
mAbs
P3 mAb (IgM, k), recognizes NeuGc-containing gangliosides and
sulfated glycolipids (Vazquez et al., 1995). P3 mAb was puri-
ﬁed from ascitic ﬂuid by gel ﬁltration chromatography using
a Sephacryl S-300 high-resolution column (Pharmacia) equili-
brated with PBS containing 0.5M NaCl. E1 mAb (IgM, k, anti-
GM2), was used as isotype control. Anti-CD8a and anti-CD4a
antibodies (IgG2b, k) were puriﬁed from supernatant of YTS
169.4.2.1 and YTS 191.1.1.2, respectively (Cobbold et al., 1984).
CELLS
Murine breast cancer F3II cells and melanoma B16-F10 cells were
grown in RPMI-1640 medium (Gibco), supplemented with 10%
fetal calf serum (FCS), 10U/mL penicillin, and 10mg/mL strep-
tomycin. Tumor cells were counted and the viability was greater
than 90%, as assayed by trypan blue exclusion test.
IMMUNIZATION PROTOCOLS
Induction of antibody response against P3 mAb
To evaluate the relevance of the immunization route for P3
mAb immunogenicity, BALB/c mice were immunized with four
www.frontiersin.org April 2012 | Volume 3 | Article 94 | 7
Martínez et al. P3: Immunogenic and immunoregulatory antibody
biweekly dose of 50μg of P3 mAb in PBS subcutaneous (s.c.),
intramuscular (i.m.), or intraperitoneally (i.p.). To evaluate the
importance of the dose number and the presence of adjuvant,
BALB/c mice were immunized with one or four dose of 50 μg
of P3 mAb, at 2 weeks intervals, subcutaneously, in the presence
or absence of Freund’s adjuvant. C57BL/6 and NMRI mice were
immunized with four dose of 50μg of puriﬁed P3 mAb in PBS,
at 2 weeks intervals, subcutaneously. Serum samples were taken
before the ﬁrst and 7 days after each immunization.
Antibody response induction against P3 mAb in CD8+ T cells
depleted mice
To determine the moment at which CD8+ and CD4+ T cells par-
ticipate in the induction of the anti-P3mAb response, three groups
of BALB/c mice were immunized four times at 2 weeks intervals,
subcutaneously, with 50μg of P3 mAb and were inoculated with
1mg of anti-CD8a or anti-CD4 antibody intraperitoneally once
before the ﬁrst, the second or the third dose of P3 mAb immuniza-
tion, respectively. P3 mAb immunized mice without anti-CD8a
or anti-CD4 antibody treatment were used as control. Serum
samples were taken before the ﬁrst and 7 days after the fourth
immunization.
P3 mAb induction of in vivo stimulation of CD8+ T cells
BALB/c and C57BL/6 mice were immunized subcutaneously
with 50μg of P3 or E1 mAbs four times at 2 weeks interval.
Three days after last immunization mice were inoculated with
1mg of anti-CD8a antibody intraperitoneally followed by two
daily doses of 50μg of P3 or E1 mAbs, intravenously. Finally,
24 h after mice were sacriﬁced and their inguinal lymph nodes
were extracted to analyze the number of CD8+ T cell by ﬂow
cytometry.
Allogeneic tumor rejection protocol
BALB/c mice were immunized four times at 2 weeks intervals, sub-
cutaneously, with 50μg of P3 mAb. Eight days after the ﬁrst P3
mAb immunization mice were inoculated with breast tumor cell
line F3II (2× 105 cells per mouse, subcutaneously) and 21 days
later with the allogeneic melanoma cell line B16-F10 (5× 105 cells
per mouse, subcutaneously). C57BL/6 and BALB/c mice inocu-
lated only with melanoma B16-F10 cells were used as positive and
negative control, respectively. The tumor sizemeasurement started
7 days after melanoma inoculation, twice a week. For ethical rea-
sons, animals were sacriﬁced when the general condition of the
animals was affected.
P3 mAb induction of lymphocytes population recovery after
cyclophosphamide treatment
BALB/c mice were treated with two doses of cyclophosphamide
(200mg/kg) at 4 days interval. Two days later mice were inocu-
lated with 50μg of P3 or E1 mAbs, intravenously. After 48 h mice
were sacriﬁced and their inguinal lymph nodes were extracted,
cell number was counted used Neubauer’s chamber. Percent of
each lymphocytes population (CD4+ T,CD8+ T, and B cells) were
measured by ﬂow cytometry, taken PBS treated group as 100%.
ELISA
Solid phase ELISA was performed as previously described (Rei-
tan and Hannestad, 2002), using 96-well polystyrene MaxiSorp
microtiter plates (Nunc) which were coated with 10 μg/mL of
puriﬁed P3 mAb and incubated with preimmune or hyperim-
mune sera dilute 1:100. Alkaline phosphatase-conjugated goat
anti-mouse IgG (Fcγ-speciﬁc, Jackson ImmunoresearchLaborato-
ries)was used as second antibody. The reactionwas developedwith
p-nitro-phenyl phosphate substrate (Sigma) in diethanolamine
buffer (pH 9.8). The absorbance was measured at 405 nm in an
ELISA reader (Organon Teknika).
FLOW CYTOMETRY
Cells were obtained from inguinal lymph nodes and were incu-
bated with PE-conjugated anti-mouse CD8a, FITC-conjugated
anti-mouse CD4 and FITC-conjugated anti-mouse B220 (BD
Pharmingen) for 30min at 4˚C and then washed with PBS twice.
Cell surface antigen expression was evaluated by single- or double-
immunoﬂuorescence staining. Analysis was performed with a
FACScan analyzer (Becton Dickinson, USA) and WinMDI 2.9
software.
STATISTICAL ANALYSIS
Differences in IgG antibody response against P3 mAb were evalu-
ated by Mann–Whitney test. The comparison between the num-
ber of lymphocytes in the experimental groups treated in vivo
with anti-CD8a antibody or cyclophosphamide were analyzed by
KruskalWallis andDunnett t -test. The differences in the percent of
B16-F10 incidence was analyzed using Pearson’s chi-square (χ2)
test. The differences were considered signiﬁcant when p ≤ 0.05.
All statistical tests were one-tailed, and conducted using SSPS for
Windows version 11.5.1 software.
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APPENDIX
FIGUREA1 | Kinetic of IgG antibodies response in BALB/c mice.
Mice were immunized with one (1d) or four (4d) doses of P3 mAb or an
isotype control mAb in PBS or emulsiﬁed in Freund’s adjuvant (FA).
Humoral response were tested against P3 mAb (A,C) or isotype control
mAb (B,D). The blood samples were obtained before the immunization
and on days 7, 21, 35, and 49 of the immunization protocol. Sera were
diluted 1:100 and the reactivity against puriﬁed P3 mAb was assessed by
ELISA. Binding was determined using alkaline phosphatase-conjugated
goat anti-mouse IgG (Fcγ-speciﬁc). Values are expressed as means±SD
(n = 5).
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